Dulaglutide vs Epithalon
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss Agonists
DulaglutideAnti-Aging & Longevity
Epithalon- Summary
- Dulaglutide (brand name Trulicity) is a once-weekly GLP-1 receptor agonist approved by the FDA for type 2 diabetes management and cardiovascular risk reduction. It consists of two GLP-1 analog chains fused to a modified IgG4 Fc fragment, extending its half-life to approximately 5 days. While primarily a diabetes medication, it produces meaningful weight loss and has established cardiovascular outcomes data from the REWIND trial.
- Epithalon is a synthetic tetrapeptide developed from the pineal gland extract Epithalamin by Russian scientist Dr. Vladimir Khavinson. It is one of the most researched longevity peptides, known for activating telomerase and extending telomere length — the molecular hallmarks of cellular aging.
- Half-Life
- ~5 days
- 2–4 hours
- Admin Route
- SubQ
- SubQ, Sublingual
- Research
- —
- —
- Typical Dose
- 0.75 mg → 1.5 mg
- 5–10 mg total per cycle
- Frequency
- Once weekly
- 0.5–1 mg daily
- Key Benefits
- FDA-approved for type 2 diabetes
- Once-weekly subcutaneous dosing via auto-injector pen
- Reduces HbA1c by approximately 1.1–1.6%
- Modest weight loss of 1.5–3 kg at approved doses
- Demonstrated cardiovascular risk reduction (REWIND trial)
- Established long-term safety profile
- Renal protective effects in CKD
- Activates telomerase enzyme, extending telomere length
- May slow cellular and biological aging
- Regulates melatonin production and circadian rhythms
- Improves sleep quality
- Powerful antioxidant properties
- May reduce incidence of age-related diseases
- Supports immune system function
- Studied for cancer prevention properties in animal models
- Side Effects
- Nausea (most common, typically transient)
- Diarrhea
- Vomiting
- Decreased appetite
- +3 more
- Injection site irritation (mild)
- Temporary sleep changes during cycle (usually improves)
- Rare: fatigue
- Stacks With
- —
- —